Vivos (RDGL) Liabilities and Shareholders Equity (2010 - 2025)
Vivos (RDGL) reported Liabilities and Shareholders Equity of $1.9 million for Q4 2025, down 16.38% on a YoY basis from $2.2 million in Q4 2024, and down 18.63% sequentially from $2.3 million in Q3 2025.
Vivos (RDGL) Liabilities and Shareholders Equity (2010 - 2025) Analysis & Trends
Vivos (RDGL) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $1.9 million in Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 16.38% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2025 stood at $10.2 million (up 54.46% YoY), and the FY2025 full-year result was $1.9 million, down 16.38% from the prior year.
- Liabilities and Shareholders Equity declined to $1.9 million in Q4 2025, from $2.3 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.3 million in Q1 2025 to a low of $1.1 million in Q2 2022.
- A 5-year average of $1.9 million and a median of $1.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity surged 3429.68% in 2021 and sank 50.37% in 2022, its largest moves.
- Tracing RDGL's Liabilities and Shareholders Equity over 5 years: stood at $1.6 million in 2021, then increased by 6.64% to $1.7 million in 2022, then decreased by 7.61% to $1.6 million in 2023, then surged by 38.71% to $2.2 million in 2024, then fell by 16.38% to $1.9 million in 2025.
- Business Quant data shows RDGL's Liabilities and Shareholders Equity at $1.9 million in Q4 2025, $2.3 million in Q3 2025, and $2.8 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 6.63 Bn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 37.13 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | 10.46 Bn |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 31.92 Bn |
| 10 | Vivos | 27.16 Mn | 25.60 Mn | -3,105.00 | 1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.87 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 2.78 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Dec 31, 2024 | 2.23 Mn |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 1.57 Mn |
| Jun 30, 2023 | 1.79 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.74 Mn |
| Sep 30, 2022 | 2.05 Mn |
| Jun 30, 2022 | 1.11 Mn |
| Mar 31, 2022 | 1.31 Mn |
| Dec 31, 2021 | 1.63 Mn |
| Sep 30, 2021 | 2.04 Mn |
| Jun 30, 2021 | 2.23 Mn |
| Mar 31, 2021 | 2.52 Mn |